Scholars Central

ArticlePublished 30 Jan 2024

Ups and Downs in MS Therapeutics

Authors: Abdul Aftab, Pankaj Majlumdar

Journal of Multiple Sclerosis

Volume 11 · Issue 1 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Over the past three decades, there has been a remarkable surge in the approval of drugs for treating Multiple Sclerosis (MS), with the number now exceeding 15 options, including various dosages and generics. However, while these treatments have primarily targeted the inflammatory activity underlying relapses, the progressive aspects of MS, characterized by a gradual worsening of disability without relapses, remain inadequately addressed. Siponimod and Ocrelizumab have emerged as crucial drugs approved for treating progressive forms of MS, particularly primary progressive and secondary progressive MS. Despite their benefits for patients experiencing clinical relapses or displaying disease activity in MRI scans, their use is limited to those with active disease as per regulators in the US and Europe. This leaves a significant treatment gap for patients with progressive MS lacking active disease. Addressing this gap, Jeremy Chataway and colleagues conducted a multi-arm phase 2b trial named the Multiple Sclerosis Secondary Progressive Multi-Arm Randomization Trial (MS-SMART), as reported in The Lancet Neurology. The trial selected three experimental drugs—amiloride, fluoxetine, and riluzole—based on an extensive systematic review of 532 potential treatment options. These drugs target axonal pathology and neuroprotection and boast a robust safety profile in humans, rendering them suitable candidates for testing in progressive MS. This study underscores the urgent need for more effective treatments to fill the existing gap in care for patients with progressive MS, particularly those without active disease

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Multiple Sclerosis.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Multiple Sclerosis
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Abdul Aftab”
  • BylineArticles whose byline prints “Pankaj Majlumdar”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels